Replies to post #14521 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Thanks Silvr, I figured he would have a good cause for selling, especially going into the results coming out for Libigel.

Acasti is an interesting company. I got a kick out of one of their directors Dr. Kottayil. According to his bio on the site:

He directed business operations at Unimed Pharmaceuticals Inc., a division of Solvay Pharmaceuticals, now Abbvie. He played a key role in product development and obtaining FDA approval for the company’s NDA products most notably ANDROGEL®. ANDROGEL was the market leader in male hormone replacement therapy for well over a decade with peak annual revenues exceeding US$1 billion.

From Acasti's prospectus filing

Shore Pharma LLC, an entity controlled by Vimal Kavuru, the Chair of our board of directors, and SS Pharma LLC, the beneficial owner of 5.5% of our common shares prior to the Private Placement Offering, each a related party of ours, participated in the Private Placement Offering.

Prospectus

Good to see the Chairman pony up his own money.


I might invest in them as well. Especially if Samy is also taking a stake.